• Neoprobe Corp., of Dublin, Ohio, appointed Mark Pykett president and CEO.

• Neuro-Biotech Corp., of Basel, Switzerland, named Rustern Yusupov vice president of marketing.

• Neurotune AG, of Zurich, Switzerland, said that Raimund Eckel will form the board, together with Gerhard Musshafen and Bruno Oesch. Armin W. Mader assumed the role of CEO.

• PanOptica Inc., of Mount Arlington, N.J., appointed Colin Goddard to its board.

• Pepscan Therapeutics BV, of Lelystad, the Netherlands, appointed Michiel Lodder chief business officer.

• Portola Pharmaceuticals Inc., of South San Francisco, appointed James Topper to its board.

• PTC Therapeutics Inc., of South Plainfield, N.J., appointed Robert J. Spiegel chief medical officer.

• Regulus Therapeutics Inc., of La Jolla, Calif., named Lars Karlsson vice president of immunology and fibrosis.

• Roche Group, of Nutley, N.J., added Janet Hammond as vice president of translational medicine-virology in pharmaceutical research and early development.

• Rosetta Genomics Ltd., of Philadelphia, elected Brian A. Markison to its board.

• Scynexis Inc., of Research Triangle Park, N.C., named Dennis Schmatz strategic advisor.

• Synergy Pharmaceuticals Inc., of New York, appointed Laura Barrow vice president of clinical operations.

• Tobira Therapeutics Inc., of Manalapan, N.J., named Andrew Hindman president and CEO.

• Topica Pharmaceuticals Inc., of Palo Alto, Calif., elected David E. Cohen to its board.

• Trevena Inc., of King of Prussia, Pa., appointed Arthur Fratamico chief business officer.

• Valeant Pharmaceuticals International Inc., of Mississauga, Ontario, appointed J. Michael Pearson chairman. Pearson also agreed to continue his role as CEO through February 2017.